Synthesis of the Antagonist of the GalR2 Galanin Receptor and Studies of Its Biological Activity in Ischemia and Reperfusion of the Rat Heart In Vivo

[1]  O. Pisarenko,et al.  Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  O. Kunduzova,et al.  Cardioprotective properties of N-terminal galanin fragment (2-15) in experimental ischemia/reperfusion injury , 2017, Oncotarget.

[3]  O. Kunduzova,et al.  Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment , 2017, Oncotarget.

[4]  Zhenwen Zhang,et al.  Effect of endogenous galanin on glucose transporter 4 expression in cardiac muscle of type 2 diabetic rats , 2014, Peptides.

[5]  T. Bártfai,et al.  Galanin Receptors and Ligands , 2012, Front. Endocrin..

[6]  P. Jakeman,et al.  Antioxidative peptides: enzymatic production, in vitro and in vivo antioxidant activity and potential applications of milk-derived antioxidative peptides , 2012, Amino Acids.

[7]  B. Kofler,et al.  The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. , 2007, Pharmacology & therapeutics.

[8]  Jun Ren,et al.  Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. , 2007, Current diabetes reviews.

[9]  T. Bártfai,et al.  M871—A Novel Peptide Antagonist Selectively Recognizing the Galanin Receptor Type 2 , 2006, International Journal of Peptide Research and Therapeutics.

[10]  C. Visser,et al.  Apoptosis in myocardial ischaemia and infarction , 2002, Journal of clinical pathology.

[11]  M. Bayne,et al.  Cloning and Expressional Characterization of a Novel Galanin Receptor , 1997, The Journal of Biological Chemistry.